Market Overview

UPDATE: Deutsche Bank Initiates Quintiles Transnational at Buy on Multiple Positive Factors

Share:
Related
Top 4 Mid-Cap Stocks In The Medical Laboratories & Research Industry With The Lowest PEG Ratio
UPDATE: Deutsche Bank Reiterates On Quintiles Transnational On Mixed Factors

In a report published Tuesday, Deutsche Bank analyst Darren Lehrich initiated coverage on Quintiles Transnational (NYSE: Q) with a Buy rating and $51.00 price target.

In the report, Deutsche Bank noted, “In an environment characterized by secular tailwinds and increased penetration of CRO outsourcing, we believe Q's operational scale, breadth of service capabilities, and management team experience position it better than any other player in the CRO landscape. Bottom line: we believe Q is a best in breed player in pharma services, and we think Q should be a core large-cap holding for HC services investors. Initiate Buy w/$51 PT (22.5x 2014E EPS of $2.27). Our tgt P/E represents a 15% premium to the peer group's 10-yr fwd P/E avg of 19.5x, justified due to Q's visible backlog and the co's ability to absorb market share gains more profitably than peers due to its scale.”

Quintiles Transnational closed on Monday at $43.53.

Latest Ratings for Q

DateFirmActionFromTo
Feb 2015CitigroupMaintainsBuy
Feb 2015BarclaysMaintainsOverweight
Feb 2015JefferiesMaintainsHold

View More Analyst Ratings for Q
View the Latest Analyst Ratings

Posted-In: Darren Lehrich Deutsche BankAnalyst Color Initiation Analyst Ratings

 

Related Articles (Q)

Around the Web, We're Loving...